EVP Sells $20.7M in Amgen Stock Following Option Exercise
AMGN sits 48% above its 52-week low of $261.43.
Summary
Amgen's EVP of Operations, Esteban Santos, sold $20.7 million worth of common stock after exercising options, reducing his direct holdings.
Key Events · Ownership and Investor Activity · AMGN
-
Executive Sells Significant Stake
Esteban Santos, Amgen's EVP of Operations, sold 54,792 shares of common stock for a total value of $20.7 million.
-
Option Exercise Preceded Sale
The sale followed the exercise of options to acquire 54,792 shares for $9.27 million, indicating a net cash-out from the transaction.
-
Discretionary Sale Near 52-Week High
The transaction was not executed under a 10b5-1 plan and occurred while Amgen's stock is trading near its 52-week high, suggesting the executive is locking in profits.
Analysis · AMGN · Life Sciences
This Form 4 filing indicates a significant sale of Amgen stock by Esteban Santos, EVP of Operations. While a portion of the $20.7 million sale was likely to cover the exercise price of options and associated taxes, the transaction represents a substantial cash-out by a key executive. The sale occurred as Amgen's stock trades near its 52-week high, suggesting the executive is realizing gains. This discretionary sale, not under a 10b5-1 plan, could be interpreted by investors as a slightly negative signal regarding insider sentiment, despite the routine nature of option exercises.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMGN was trading at $386.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.9B. The 52-week trading range was $261.43 to $391.29. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.